Skip to content
RG+A Customer Creed
Our Core Values
Ellen J. Gordon, Ph.D.
Bruce Duncan, Ph.D.
Treatment Areas and Therapeutic Drug Classes
Enhancing forecast precision by simulating patient treatments
Abandoned by Nielsen? RG+A can help you now!
Webinar: Forecasting Across Lines of Therapy
Presentation: Forecast Treatment across Multiple Therapy Lines
Managed Care’s Perspective: Best Practices in Payer-Manufacturer Relationships
Doing More with Less: Utilizing Small Sample Analytics to Get the Most Out of Your Research Budget
Forecasting Physician Treatment Decisions across Multiple Lines of Therapy
Better Answers with Imprecise Data
Attribute Importance Ratings: Are We Learning Anything We Don’t Already Know?
Product Positioning for an Innovative In-Home Medical Device
Hazardous Drug Detection for Employee Safety
Assessing Market Potential and Development Strategy
Pricing and Volumetric Forecasting for an Orphan Drug
Using DPS®/Conjoint to Formulate a Competitive Response
Forecasting for Multiple Indications within the ADHD Market
Generic Competition Assessment Among Payers Using PV Scope®
Using Co-Creation with Payers to Support Optimal Product Profile Development and Clinical Trial Design
Applying Dynamic Practice Simulation (DPS) to Development and Commercialization Strategy
Developing Competitive Contracting Strategies using Contract Simulation®
Contracting Strategy Development using Qualitative Conjoint to Segment Community Oncology Practice Managers
Forecasting and Strategy Development for a Neurological Product
Feature Optimization via Qualitative Conjoint to Combat Competitive Threat in the Vascular Device Space
Areas of Expertise
Strategic Risk Modeling
Product Development & Positioning
Business Development and Licensing
Orphan and Ultra-Orphan Tools
Dynamic Practice Simulation® (DPS®)
Dynamic Practice Simulation® Line of Therapy
Health Payer Insights (HPI)
Wisdom of Crowds
Join our Mailing List
It seems we can’t find what you’re looking for. Perhaps searching can help.